Drap | Pakistan

The Drug Regulatory Authority of Pakistan (Drap) on Sunday dismissed reports of price hikes in essential medicines across the country, stating that the rates have not “undergone any upward revision”. The statement comes as stakeholders in recent news reports alleged that an unprecedented increase in medicine prices had been observed since February 2024. Pakistan Drug Lawyers Forum President Noor Muhammad Mehr, a day earlier, told Dawn that the price of the insulin delivery device HumaPen Ergo II had increased by 114 per cent The Pakistan Pharmaceutical Manufacturers Association (PPMA), however, claimed that the prices of essential medicines had remained unchanged despite a more than 20 per cent rise in fuel prices. In its statement, Drap said that it “strongly refutes the factually incorrect news reports circulating on various media channels regarding the recent increase in prices of medicines”. The regulatory body stated that medicine supply in Pakistan remained “unaffected” by the conflict in the Middle Eas...

The Drug Regulatory Authority of Pakistan (DRAP) has rejected reports of a recent increase in the prices of essential medicines, terming such claims baseless.

The Drug Regulatory Authority of Pakistan (DRAP) on Thursday seized multiple batches of counterfeit medicines during a nationwide crackdown.

Pakistan’s Drug Regulatory Authority (Drap) on Tuesday ordered the withdrawal of a batch of Anarob antibiotic drip after it was found to contain harmful levels of bacterial toxins. Anarob Infusion is an intravenous antibiotic drip containing metronidazole, commonly used in hospitals to treat serious bacterial infections in the stomach, skin, lungs, joints, and other parts of the body when oral medicines are not effective. A medical product alert issued today said Drap’s Central Drugs Laboratory had informed the body that samples of the drug were declared “substandard” due to being out of specification for bacterial endotoxins. “Use of this contaminated infusion may cause severe adverse reactions such as fever, chills, septic shock and life-threatening complications. Hospitalised and immunocompromised patients are at the greatest risk,” the authority warned. It said its field force and Provincial Drug Control departments were directed to immediately conduct market surveys to detect and remove the affected batc...

ISLAMABAD - Federal Minister for Health, Mustafa Kamal, visited Drug Regulatory Authority of Pakistan (DRAP) to review the newly launched Online Registration and Licensing System for medical devices on Monday.

ISLAMABAD: The Drug Regulatory Authority of Pakistan (DRAP) has issued an alert to recall Amoxil Suspension and Amoxil Forte Suspension due to quality defect. GlaxoSmithKline (GSK) Pakistan has initiated a voluntary recall of multiple batches of its widely used antibiotics — Amoxil Suspension and Amoxil Forte Suspension — following a quality concern related to defective […]

The Drug Regulatory Authority of Pakistan (Drap) on Tuesday directed three pharmaceutical companies to recall “substandard” medical devices from the market and advised pharmacists and chemists to stop supplying these products. “[The] Central Drugs Laboratory Karachi informed the Drug Regulatory Authority of Pakistan that the samples of the below-mentioned medical devices have been declared as ‘Substandard’,” an alert issued by Drap stated. The alert identified Zindagi Auto Disable Syringe 5ml, the Ultra Fine SMD Painless Syringe 5ml and Ultra Fine SMD Painless Syringe 3ml as the substandard devices. “Use of these syringes, in invasive or intravenous procedures, poses a significant risk of introducing microbial contaminants into the patient’s body, which may result in localised infections, abscesses, or life-threatening systemic infections, particularly in immunocompromised individuals,” Drap said. “All pharmacists and chemists working at distribution and pharmacies should immediately check their stocks and st...